CENTURY THERAPEUTICS, INC.

(IPSC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Century Therapeutics, Bristol Myers Squibb Sign Cancer Research Collaboration Agreement

01/10/2022 | 08:24am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 0.56% 77.13 Delayed Quote.23.02%
CENTURY THERAPEUTICS, INC. -5.53% 8.37 Delayed Quote.-44.14%
STEM, INC. -10.80% 6.94 Delayed Quote.-58.99%
All news about CENTURY THERAPEUTICS, INC.
05/23HC Wainwright Starts Century Therapeutics at Buy With $27 Price Target
MT
05/17Piper Sandler Adjusts Century Therapeutics' Price Target to $22 From $38, Reiterates Ov..
MT
05/16Century Therapeutics Q1 Net Loss Narrows; Posts Revenue of $1.1 Million
MT
05/16CENTURY THERAPEUTICS, INC. Management's discussion and analysis of financial condition..
AQ
05/16Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/16Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business..
GL
05/12William Blair Initiates Coverage on Century Therapeutics With Market Perform Rating
MT
05/10CENTURY THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/03Century Therapeutics to Present at Upcoming Investor Conferences
GL
05/03Century Therapeutics to Present at Upcoming Investor Conferences
GL
More news
Analyst Recommendations on CENTURY THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 218 M - -
Net income 2022 -133 M - -
Net cash 2022 127 M - -
P/E ratio 2022 -3,89x
Yield 2022 -
Capitalization 521 M 521 M -
EV / Sales 2022 1,81x
EV / Sales 2023 19,4x
Nbr of Employees 179
Free-Float 63,4%
Chart CENTURY THERAPEUTICS, INC.
Duration : Period :
Century Therapeutics, Inc. Technical Analysis Chart | IPSC | US15673T1007 | MarketScreener
Technical analysis trends CENTURY THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,86 $
Average target price 25,00 $
Spread / Average Target 182%
EPS Revisions
Managers and Directors
Osvaldo Flores Chief Executive Officer & Director
Douglas Carr Vice President-Finance & Operations
Joseph Jimenez Chairman
Hyam I. Levitsky President-Research & Development
Luis Borges Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CENTURY THERAPEUTICS, INC.-44.14%521
MODERNA, INC.-45.81%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-27.91%38 497
SEAGEN INC.-9.87%25 649
ICON PUBLIC LIMITED COMPANY-29.74%17 688